Sign In
Buy ALNY
$297.69
+5.53 (+1.89%)
At Close: Jun 09, 2026
Coronavirus map LIVE: UK announces another 202 deaths in past 24 hours - total hits 41,481
04:58am, Saturday, 13'th Jun 2020
THE COMMON cold could help provide immunity to the deadly coronavirus for up to 17 years, a new study has found. It comes as the UK confirmed an additional 202 coronavirus deaths over the past 24 hour
Akcea: Uninteresting Slow Growth Stock With Long-Term Potential (NASDAQ:AKCA)
05:03pm, Friday, 12'th Jun 2020
AKCA is a highly uninteresting stock - perhaps just the kind we need in these times. It has two approved products and a long pipeline in rare diseases. AKCA is
Regeneron starts two trials of two-antibody antiviral cocktail for Covid-19
03:42pm, Friday, 12'th Jun 2020
The company plans to test REGN-COV2 - consisting of the SARS-CoV-2-specific antibodies REGN10933 and REGN10987 - in four populations, including infected patients and uninfected people at high risk of
Scopus Bio preps trials of gene-silencing immuno-oncology drug -
11:13am, Friday, 12'th Jun 2020
Scopus BioPharma has licensed a gene-silencing drug from California’s City of Hope hospital that is due to start
Alnylam Announces Publication of ENVISION Phase 3 Study Results for Givosiran in the New England Journal of Medicine
09:07pm, Wednesday, 10'th Jun 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that pivotal results from the ENVISION Phase 3 study of givosiran, an RNAi therapeutic targeting am
Small Caps Build Steam And Biotechs Remain Well-Positioned
02:15pm, Wednesday, 10'th Jun 2020
Economic optimism has broadened the market rally. Small caps had lagged significantly and are now catching-up as they narrow the performance gap. The Federal Re
‘Are you immune?’ The new class system that could shape the Covid-19 world
09:30am, Wednesday, 10'th Jun 2020
Experts suspect – but there is no proof – that those who have developed antibodies will have immunity. The implications could be wide-ranging
Sorrento COVIDTRAP Update, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:SRNE)
08:40pm, Monday, 08'th Jun 2020
Sorrento announced a positive update on COVIDTRAP. Blueprint announced a strong trial performance. Alnylam's Lumasiran trial in phase 3 provides an encouraging
Clinical Data Reaffirm That Lumasiran Will Almost Certainly Be Alnylam's Third Commercial Product (NASDAQ:ALNY)
07:37pm, Monday, 08'th Jun 2020
Full results from the pivotal ILLUMINATE-A study support the efficacy of the drug in treating PH1, with meaningful improvements in urinary oxalate levels in the
Coronavirus update: Global death tally tops 400,000; Health experts urge police to stop using tear gas on anti-racism protesters
03:16pm, Monday, 08'th Jun 2020
The number of deaths from the coronavirus that causes COVID-19 rose above 400,000 on Monday, as anti-racism protests swept the U.S. and much of the rest of...
Alnylam Reports Positive Phase III Results on Lumasarin
02:00pm, Monday, 08'th Jun 2020
Alnylam (ALNY) reports positive phase III results from the ILLUMINATE-A study on lumasiran.
Alnylam Pharmaceuticals : BIO - Targeting 'Undruggable' Diseases | MarketScreener
01:05pm, Monday, 08'th Jun 2020Regeneron: Growth Plans In Immuno-Oncology (ASCO Update) (NASDAQ:REGN)
11:08am, Monday, 08'th Jun 2020
REGN has gone from doormat to leader in short order. There have been multiple drivers of this, one of which is discussed below: immuno-oncology (IO). Behind the
Alnylam's shares dip as analyst backs rival after rare disease data reveal -
11:03am, Monday, 08'th Jun 2020
Alnylam has revealed the data that forms the basis of its filings for its latest rare disease drug contender, lumasiran, but shares dipped after an analyst suggested it could be outperformed by a con
